Niki Arrowsmith05.16.13
Natick, Mass.-based Boston Scientific Corp. has received the CE mark for its Rythmia mapping system, a next-generation 3-D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures to treat a variety of conditions in which the heart beats abnormally. Some of those conditions include atrial flutter, atrial fibrillation and ventricular tachycardia. Boston Scientific is offering the Rhythmia mapping system with the company’s 64 electrode Intellamap Orion mapping catheter, which also has received CE mark approval. The combination, part of the 2012 Rhythmia Medical acquisition, is designed to provide electrophysiologists with accurate, high-resolution electro-anatomical maps.
“In a pair of independent clinical studies, we repeatedly showed the Rhythmia Mapping System can rapidly generate and display high density electro-anatomical maps that allowed clinicians to effectively diagnose and treat even the most complex patients,” said Hiroshi Nakagawa, M.D., Ph.D., professor of medicine and director of the clinical catheter ablation program at the University of Oklahoma Health Sciences Center and one of the principle investigators in the studies. “The Intellamap Orion catheter has a sophisticated 64 electrode design and deployable basket that provided a high degree of maneuverability.”
Mapping and navigation systems have become a standard tool for physicians performing catheter ablations, and current systems demand tradeoffs between accuracy and speed. A more accurate, high-resolution image may improve a physician’s ability to select the appropriate site to ablate, improving procedural efficacy. Similarly, increasing the speed at which a mapping system can provide a high-resolution map may significantly reduce procedure time. The Rhythmia mapping system is designed to increase speed and improve density of mapping compared to existing systems, potentially offering significant benefit to patients, physicians and healthcare systems.
“We believe the Rhythmia mapping system can become a leader in EP mapping with unparalleled speed, clarity and simplicity which should enable electrophysiologists to perform procedures with great efficiency and precision,” said Pete Sommerness, general manager of electrophysiology at Boston Scientific. “Bringing the Rhythmia system to our electrophysiology customers is a major step toward realizing our vision to redefine ablation technology.”
The Rhythmia Mapping System is designated an investigational device by the U.S. Food and Drug Administraion and not available for sale in the United States.
“In a pair of independent clinical studies, we repeatedly showed the Rhythmia Mapping System can rapidly generate and display high density electro-anatomical maps that allowed clinicians to effectively diagnose and treat even the most complex patients,” said Hiroshi Nakagawa, M.D., Ph.D., professor of medicine and director of the clinical catheter ablation program at the University of Oklahoma Health Sciences Center and one of the principle investigators in the studies. “The Intellamap Orion catheter has a sophisticated 64 electrode design and deployable basket that provided a high degree of maneuverability.”
Mapping and navigation systems have become a standard tool for physicians performing catheter ablations, and current systems demand tradeoffs between accuracy and speed. A more accurate, high-resolution image may improve a physician’s ability to select the appropriate site to ablate, improving procedural efficacy. Similarly, increasing the speed at which a mapping system can provide a high-resolution map may significantly reduce procedure time. The Rhythmia mapping system is designed to increase speed and improve density of mapping compared to existing systems, potentially offering significant benefit to patients, physicians and healthcare systems.
“We believe the Rhythmia mapping system can become a leader in EP mapping with unparalleled speed, clarity and simplicity which should enable electrophysiologists to perform procedures with great efficiency and precision,” said Pete Sommerness, general manager of electrophysiology at Boston Scientific. “Bringing the Rhythmia system to our electrophysiology customers is a major step toward realizing our vision to redefine ablation technology.”
The Rhythmia Mapping System is designated an investigational device by the U.S. Food and Drug Administraion and not available for sale in the United States.